Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder [0.03%]
新型GLP-1受体激动剂索马鲁肽治疗酒精使用障碍的潜在疗效
Tingting Liu,Fuqiang Shi,Zhihua Guo et al.
Tingting Liu et al.
Alcohol use disorder (AUD) is a prevalent neuropsychiatric disorder with serious health and social consequences. However, few licensed and successful pharmacotherapies exist for heterogeneous and complex disorders such as AUD, and these are...
Diversion and Abuse of Prescribed Methylphenidate - A Survey of an Outpatient Clinic for Adult Persons with ADHD [0.03%]
门诊部注意力缺陷多动障碍成人患者对处方右旋苯丙胺的滥用调查
Mona Abdel-Hamid,Naomi Lyons,Michael Specka et al.
Mona Abdel-Hamid et al.
Challenges Related to the Implementation of Measurement-Based Care for the Treatment of Major Depressive Disorder: A Feasibility Study [0.03%]
基于测量的护理在治疗重度抑郁症中实施的相关挑战：一项可行性研究
Emytis Tavakoli,Angela Xiang,Mohamed I Husain et al.
Emytis Tavakoli et al.
Measurement-based care (MBC) involves systematically assessing patients' symptoms and adverse events using standardized scales to guide treatment. While MBC has been shown to enhance the quality of care and outcomes in the pharmacotherapy o...
Pharmacological Treatment of Autism Spectrum Disorder: A Systematic Review of Treatment Guidelines [0.03%]
自闭症谱系障碍的药物治疗：治疗指南系统综述
Sota Tomiyama,Kazunari Yoshida,Hideaki Tani et al.
Sota Tomiyama et al.
Currently available systematic reviews on the pharmacological treatment of autism spectrum disorder (ASD) do not encompass all the evidence, as they exclude guidelines issued by national or local authorities that are not indexed in search e...
Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes [0.03%]
关于治疗急性精神病的成人精神分裂症患者的Xanomeline-Trospium：安全性和耐受性结果的系统评价和meta分析
Taro Kishi,Leslie Citrome,Kenji Sakuma et al.
Taro Kishi et al.
The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia...
Therapeutic Drug Monitoring of Cariprazine - Updated Values for a Dose-Related Reference Range [0.03%]
卡利拉嗪治疗药物监测-与剂量相关的参考范围更新值
Fabian Sattaf,Maike Scherf-Clavel,Stefan Unterecker et al.
Fabian Sattaf et al.
Dose-related reference ranges can be used in therapeutic drug monitoring to monitor pharmacotherapy. The deviation of a measured serum concentration from the expected serum concentration at the corresponding dose can thus be identified earl...
Development of a Genetic Test Indicating Increased AVP/V1b Signalling in Patients with Acute Depression [0.03%]
抑郁症患者遗传学检测的开发：提示AVP/V1b信号通路增强型
Marcus Ising,Florian Holsboer,Marius Myhsok et al.
Marcus Ising et al.
A subgroup of patients with acute depression show an impaired regulation of the hypothalamic-pituitary-adrenocortical axis, which can be sensitively diagnosed with the combined dexamethasone (dex)/corticotropin releasing hormone (CRH)-test....
Rapid Antidepressant and Antisuicidal Effects of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression With or Without Low-Grade Inflammation [0.03%]
低剂量氯胺酮快速抗抑郁和抗自杀效应：一项针对难治性抑郁症患者（伴或不伴轻度炎症）的研究
Mu-Hong Chen,Tung-Ping Su,Wei-Chen Lin et al.
Mu-Hong Chen et al.
Low-grade inflammation (LGI) contributes to resistance against traditional antidepressants. However, whether the antidepressant and antisuicidal effects of ketamine on patients with treatment-resistant depression (TRD) differ between those ...